Short answer
Zymeworks Inc. (ZYME) filed its Q3 2025 10-Q quarterly report on Nov 6, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $28M (up 72.6% year over year) with net income of −$20M.
Q3 2025 key financials · XBRL
- Revenue
- $28M
- +72.6% YoY · −43.3% QoQ
- Net income
- −$20M
- +34.3% YoY · −946.0% QoQ
- Operating margin
- -80.1%
- EPS (diluted)
- −$0.26
- +33.3% YoY · −966.7% QoQ
Source: XBRL data from the Zymeworks Inc. (ZYME) Q3 2025 10-Q on SEC EDGAR. USD.
Zymeworks Inc. Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- New risk: European Commission granted conditional marketing authorization of Ziihera® in July 2025, contingent on ongoing Phase 3 trial results
- Material update: FDA accelerated approval of Ziihera® in Nov 2024 requires confirmatory trial; failure may lead to market removal impacting royalties
- Regulatory risk: NMPA conditional approval in May 2025 for zanidatamab depends on ongoing confirmatory clinical benefit verification
- Operational risk: Discontinuation of ZW171 clinical program in Sep 2025 after dose escalation phase due to unfavorable benefit-risk profile
- Financial risk: Dependence on milestone payments and royalties from Jazz’s zanidatamab commercialization; no other product revenue as of Sept 30, 2025
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Zymeworks Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.